论文部分内容阅读
目的通过系统评价有关普罗布考抗动脉粥样硬化作用的文献,评估普罗布考对动脉粥样硬化及预防再狭窄的有效性。方法在Medline数据库、Embase数据库和Cochrane图书馆和中国期刊全文数据库(CNKI)、VIP、万方数据库、中国生物医学文献数据库(CBM)中检索有关普罗布考抗动脉粥样硬化的随机对照试验,并且对纳入研究进行方法学质量评价,提取文献中有效数据采用Rev Man 5.3软件进行meta分析。结果共纳入20项随机对照试验,合计1 314例患者。Meta分析结果显示,预防PTCA再狭窄支架管腔面积[WMD 0.80,95%CI(0.41~1.20),P<0.000 01]、管腔直径[WMD 0.24,95%CI(0.17~0.30),P<0.000 01]、再狭窄率[RR=0.66,95%CI(0.56~0.78),P<0.000 01]、再狭窄程度[WMD=-11.20,95%CI(-17.02~5.38),P=0.000 02]、临床不良事件发生率[RR=0.57,95%CI(0.48~0.67),P<0.000 01]方面均优于对照组,差异有统计学意义。结论普罗布考能够改善患者动脉粥样硬化状况,有效预防支架术后再狭窄。
OBJECTIVE: To assess the effectiveness of probucol on atherosclerosis and prevent restenosis by systematically assessing the anti-atherosclerotic effects of probucol. Methods The randomized controlled trials of probucol in anti-atherosclerosis were searched in the Medline database, Embase database, Cochrane Library and CNKI, VIP, Wanfang database and CBM database. The methodological quality was evaluated in the included studies, and valid data in the literature were extracted for meta-analysis using RevMan 5.3 software. Results A total of 20 randomized controlled trials were included, totaling 1 314 patients. The results of Meta-analysis showed that the lumen area of the PTCA restenosis stent was significantly reduced (WMD 0.80, 95% CI 0.41-1.20, P 0.0001), lumen diameter WM 0.24, 95% CI 0.17-0.30, P < 0.000 01], restenosis rate [RR = 0.66,95% CI (0.56-0.78), P <0.000 01], degree of restenosis [WMD = -11.20,95% CI (-17.02-5.38), P = 0.000 02 ], The incidence of clinical adverse events [RR = 0.57,95% CI (0.48 ~ 0.67), P <0.000 01] were better than the control group, the difference was statistically significant. Conclusion Probucol can improve the status of atherosclerosis and prevent the restenosis after stenting.